Jeyakumar A, Younis T (2012) Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. Clin Med Insight Oncol 6:179–187. https://doi.org/10.4137/CMO.S6460

Article  CAS  Google Scholar 

Dempsey N, Sandoval A, Mahtani R (2023) Metastatic HER2-positive breast cancer: is there an optimal sequence of therapy? Curr Treat Options Oncol 24(9):1120–1137. https://doi.org/10.1007/s11864-023-01108-w

Article  PubMed  Google Scholar 

Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA (2016) Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol 2(6):751–760. https://doi.org/10.1001/jamaoncol.2015.6113

Article  PubMed  Google Scholar 

Esteva FJ, Katz E (2024) Tailoring neoadjuvant therapy in human epidermal growth factor receptor 2-positive early breast cancer: recent advances and strategies. JCO Oncol Prac 20(8):1046–1054. https://doi.org/10.1200/OP.23.00563

Article  Google Scholar 

Downs-Canner S, Weiss A (2024) Systemic therapy advances for her2-positive and triple negative breast cancer: what the surgeon needs to know. Clin Breast Cancer 24(4):328–336. https://doi.org/10.1016/j.clbc.2024.03.004

Article  CAS  PubMed  Google Scholar 

Harbeck N (2022) Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast 62(1):S12–S16. https://doi.org/10.1016/j.breast.2022.01.006

Article  PubMed  PubMed Central  Google Scholar 

Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, Darby SC, Taylor CW (2022) Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat Rev 105:102375. https://doi.org/10.1016/j.ctrv.2022.102375

Article  CAS  PubMed  Google Scholar 

von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M, Arpino G, Puglisi F, Giuliano M, Del Mastro L (2023) The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev 113:102500. https://doi.org/10.1016/j.ctrv.2022.102500

Article  CAS  Google Scholar 

Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22(2):101–126. https://doi.org/10.1038/s41573-022-00579-0

Article  CAS  PubMed  Google Scholar 

Geyer CE, Huang C-S, Mano MS, et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. 2018 San Antonio Breast Cancer Symposium. Abstract GS1–10. Presented December 5, 2018.

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Investigators K (2019) Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. New Engl J Med. 380(7):617–628. https://doi.org/10.1056/NEJMoa1814017

Article  Google Scholar 

Wedam S, Fashoyin-Aje L, Gao X, Bloomquist E, Tang S, Sridhara R, Goldberg KB, King-Kallimanis BL, Theoret MR, Ibrahim A, Amiri-Kordestani L, Pazdur R, Beaver JA (2020) FDA approval summary: Ado-Trastuzumab Emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res Offc J Amr Assoc Cancer Res 26(16):4180–4185. https://doi.org/10.1158/1078-0432.CCR-19-3980

Article  CAS  Google Scholar 

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer (Version 1.2024). © 2024 National Comprehensive Cancer Network, Inc. Available at: NCCN.org.

Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The National cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15(3):683–690. https://doi.org/10.1245/s10434-007-9747-3

Article  PubMed  PubMed Central  Google Scholar 

About the National Cancer Database. American College of Surgeons. Accessed June 9, 2024. https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/about/

Cobb AN, Czaja R, Jorns J, Cortina CS (2024) Breast cancer subtypes: clinicopathologic features and treatment considerations. Curr Breast Cancer Rep 16(2):150–160. https://doi.org/10.1007/s12609-024-00541-6

Article  Google Scholar 

Martinez EO, Jorns JM, Kong AL, Kijak J, Lee WY, Huang CC, Cortina CS (2022) Primary breast neuroendocrine tumors: an analysis of the national cancer database. Ann Surg Oncol 29(10):6339–6346. https://doi.org/10.1245/s10434-022-12123-w

Article  PubMed  Google Scholar 

Mehdi M, Kong AL, Frebault J, Huang S, Huang CC, Cortina CS (2021) Prognostic outcomes of signet ring cell carcinoma of the breast. J Surg Res 264:138–148. https://doi.org/10.1016/j.jss.2021.02.020

Article  PubMed  PubMed Central  Google Scholar 

Cohen LN, Flanagan C, Kong AL, Cortina CS (2024) A systematic review of sebaceous carcinoma of the breast from 2000–2023: A rare entity with high recurrence rates. Surg Oncol Insight 1(3):100074. https://doi.org/10.1016/j.soi.2024.100074

Article  PubMed  PubMed Central  Google Scholar 

Satpathy Y, Nam P, Moldovan M, Murphy JD, Wang L, Derweesh I, Rose BS, Javier-DesLoges J (2023) Comparison of capture rates of the national cancer database across race and ethnicity. JAMA Netw Open 6(12):e2350237. https://doi.org/10.1001/jamanetworkopen.2023.50237

Article  PubMed  PubMed Central  Google Scholar 

Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E. M., Francis, P. A., Gamal-Eldin, H., Gelmon, K., Geyer, C. E., Gnant, M., Guarneri, V., Gupta, S., Kim, S. B., … ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 35(2): 159–182. https://doi.org/10.1016/j.annonc.2023.11.016

Rogers C, Cobb AN, Lloren JIC, Chaudhary LN, Johnson MK, Huang CC, Teshome M, Kong AL, Singh P, Cortina CS (2024) National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat 203(2):317–328. https://doi.org/10.1007/s10549-023-07114-8

Article  CAS  PubMed  Google Scholar 

Duchesneau ED, An SJ, Strassle PD, Reeder-Hayes KE, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM (2022) Sociodemographic and clinical predictors of neoadjuvant chemotherapy in cT1-T2/N0 HER2-amplified breast cancer. Ann Surg Oncol 29(5):3051–3061. https://doi.org/10.1245/s10434-021-11260-y

Article  PubMed  PubMed Central  Google Scholar 

Puig CA, Hoskin TL, Day CN, Habermann EB, Boughey JC (2017) National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: a national cancer data base study. Ann Surg Oncol 24(5):1242–1250. https://doi.org/10.1245/s10434-016-5733-y

Article  PubMed  Google Scholar 

Houvenaeghel G, de Nonneville A, Cohen M, Viret F, Rua S, Sabiani L, Buttarelli M, Charaffe E, Monneur A, Jalaguier-Coudray A, Bannier M, Sabatier R, Gonçalves A (2022) Neoadjuvant chemotherapy for breast cancer: evolution of clinical practice in a french cancer center over 16 years and pathologic response rates according to tumor subtypes and clinical tumor size: retrospective cohort study. J Surg Res 5(3):511–525. https://doi.org/10.26502/jsr.10020251

Article  Google Scholar 

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141. https://doi.org/10.1056/NEJMoa1406281

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown L, Carr MJ, Sam C, Sun W, Whiting J, Kim Y, Lee MC (2023) Tolerance and outcomes of neoadjuvant chemotherapy in geriatric breast cancer patients. J Surg Res 283:329–335. https://doi.org/10.1016/j.jss.2022.10.092

Article  CAS  PubMed  Google Scholar 

Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC (2019) Adolescents and young adults with breast cancer have more aggressive disease and treatment than patients in their forties. Ann Surg Oncol 26(12):3920–3930. https://doi.org/10.1245/s10434-019-07653-9

Article  PubMed  Google Scholar 

Chen L, Li CI (2015) Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomark Prevent Publ Amr Assoc Cancer Res Cosponsor Amr Soc Prevent Oncol 24(11):1666–1672. https://doi.org/10.1158/1055-9965.EPI-15-0293

Article  CAS  Google Scholar 

Penner LA, Dovidio JF, Gonzalez R, Albrecht TL, Chapman R, Foster T, Harper FW, Hagiwara N, Hamel LM, Shields AF, Gadgeel S, Simon MS, Griggs JJ, Eggly S (2016) The effects of oncologist implicit racial bias in racially discordant oncology interactions. J Clin Oncol Offc J Amr Soc Clin Oncol 34(24):2874–2880. https://doi.org/10.1200/JCO.2015.66.3658

Article  Google Scholar 

Freeman JQ, Li JL, Fisher SG, Yao KA, David SP, Huo D (2024) Declination of treatment, racial and ethnic disparity, and overall survival in US patients with breast cancer. JAMA Netw Open 7(5):e249449. https://doi.org/10.1001/jamanetworkopen.2024.9449

Article  PubMed  PubMed Central